Drug Profile
Pramlintide - AstraZeneca
Alternative Names: AC-0137; AC-137; BMS-986114; Pramlintide acetate; SYMLIN; Tripro-amylinLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Amylin Pharmaceuticals
- Developer AstraZeneca
- Class Antihyperglycaemics; Macromolecular substances; Proteins
- Mechanism of Action Islet amyloid polypeptide stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 1 diabetes mellitus; Type 2 diabetes mellitus